

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Termination of Security Interest		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Wells Fargo Bank	FORMERLY Wachovia Bank	10/19/2011	National Association: UNITED STATES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	WellSpring Pharmaceutical Corporation		
<b>Street Address:</b>	5911 North Honore Avenue, Suite 211		
<b>City:</b>	Sarasota		
<b>State/Country:</b>	FLORIDA		
<b>Postal Code:</b>	34243		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 9</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
Registration Number:	3674239	GLAXAL BASE	
Registration Number:	3664440	GLAXAL BASE	
Registration Number:	2264700		
Registration Number:	1070508	DUVOID	
Registration Number:	0997843	MICATIN	
Registration Number:	0785081	DYRENIUM	
Registration Number:	0536728	EMETROL	
Registration Number:	0548626	DIBENZYLINE	
Registration Number:	0378528	GELUSIL	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(801)799-5700		
<b>Email:</b>	klanderson@hollandhart.com		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			

**CH \$240.00 3674239**

**900205572**

**TRADEMARK  
 REEL: 004648 FRAME: 0602**

Correspondent Name: Joanna L. Mull  
Address Line 1: 222 South Main Street, Suite 2200  
Address Line 4: Salt Lake City, UTAH 84101

ATTORNEY DOCKET NUMBER: 17173.0110

NAME OF SUBMITTER: Joanna L. Mull

Signature: /Joanna L. Mull/

Date: 10/26/2011

Total Attachments: 4  
source=Termination-SecurityAgmt#page1.tif  
source=Termination-SecurityAgmt#page2.tif  
source=Termination-SecurityAgmt#page3.tif  
source=Termination-SecurityAgmt#page4.tif

EXHIBIT A

TERMINATION OF SECURITY INTEREST  
(Patents and Trademarks)

This TERMINATION OF SECURITY INTEREST, dated as of October 19, 2011, is made by Wachovia Bank, National Association as the Lender ("Lender").

WHEREAS, WellSpring Pharmaceutical Corporation and WellSpring Holding Corporation, each a Delaware corporation (the "Grantor"), had granted to the Lender a security interest in certain personal property, including without limitation, a security interest in certain patents and trademarks listed on Schedule A hereto ("Patents and Trademarks"); and

WHEREAS, the Lender has agreed to terminate and release its security interest in all of such Patents and Trademarks as herein provided;

NOW, THEREFORE, for valuable consideration, the Lender hereby terminates and releases all mortgages, assignments liens and security interests granted to the Lender in Grantor's Patents and Trademarks referred to on Schedule A hereto.

{SIGNATURE PAGE FOLLOWS}

IN WITNESS WHEREOF, the Lender has caused this Termination of Security Interest to be duly executed as of the date first set forth above.

Wells Fargo Bank, National Association

By: 

Name: Timothy J. Smith

Title: Senior Vice President

STATE OF New Jersey }  
COUNTY OF Bergen }


On this 18<sup>th</sup> day of October, 2011, before me personal came Timothy J. Smith, to me known, who, being by me duly sworn, did depose and say that (s)he is Senior Vice President of Wells Fargo Bank, National Association, the entity described in and which executed the foregoing instrument; and that (s)he signed his/her name thereto was authorized to execute such document.

*Kimberly S. Correll*  
Notary Public


Notary's printed name:

Kimberly S. Correll

My commission expires: \_\_\_\_\_, 20\_\_



Schedule A

Mark	Country	Owner	Serial or Reg. No.
<i>Glaxal Base</i>	US	Wellspring Pharmaceutical Corporation	3,674,239
GLAXAL BASE	US	Wellspring Pharmaceutical Corporation	3,664,440
Design Only 	US	Wellspring Pharmaceutical Corporation	2,264,700
DUVOID	US	Wellspring Pharmaceutical Corporation	1,070,508
MICATIN	US	Wellspring Pharmaceutical Corporation	997,843
DYRENIUM	US	Wellspring Pharmaceutical Corporation	785,081
EMETROL	US	Wellspring Pharmaceutical Corporation	536,728
DIBENZYLIN	US	Wellspring Pharmaceutical Corporation	548,626
GELUSIL	US	Wellspring Pharmaceutical Corporation	378,528